StockData

Korro Bio vs Ovid Therapeutics

KRRO and OVID side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KRRO and OVID compare

Ovid Therapeutics is the larger company, worth 2.5 times as much as Korro Bio ($469M against $187M).

Korro Bio grew revenue faster over the last twelve months (−62.1% versus −76.2% for Ovid Therapeutics).

Ovid Therapeutics keeps more of each dollar of sales as profit, with a net margin of −2179% compared with −4477% at Korro Bio.

Ovid Therapeutics scores higher on the StockData Score (9 against 5 for Korro Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKRROOVID
Size and price
Market cap$187M$469M
Share price$12.71$2.40
Change, 1 year95.5%100%
Change, 5 years−95.5%−26.4%
Beta (5Y)2.431.24
Employees5823
StockData Score
Total score59 (better)
Valuation score00
Growth score01 (better)
Performance score02 (better)
Health score56 (better)
Dividend score00
Valuation
P/S78.6× (better)296×
P/B–2.2×
FCF yield−36.5%–
Growth
Revenue growth (TTM)−62.1% (better)−76.2%
Revenue growth, 5Y average−29.6%−10.5% (better)
Profitability
Operating margin−4625%−3687% (better)
Net margin−4477%−2179% (better)
FCF margin−2866%–
Return on equity–−26.0%
Return on invested capital–−160%
Financial health
Debt / equity–0.00
Current ratio9.5512.39 (better)
Altman Z-score−3.1710.36 (better)
Piotroski F-score24 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions102%75.3%
Held by insiders27.4%13.6%
Insider net buying, 12 months$15.0M (better)−$29.3K
Short interest, % of float16.4%10.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.